Fintel reports that on June 1, 2023, LEEDE JONES GABLE maintained coverage of Quipt Home Medical Corp (TSX:QIPT) with a Buy recommendation.
Analyst Price Forecast Suggests 95.02% Upside
As of June 2, 2023, the average one-year price target for Quipt Home Medical Corp is 14.06. The forecasts range from a low of 11.11 to a high of $19.42. The average price target represents an increase of 95.02% from its latest reported closing price of 7.21.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Quipt Home Medical Corp is 223MM, an increase of 35.98%. The projected annual non-GAAP EPS is 0.06.
What are Other Shareholders Doing?
FESRX - First Eagle Small Cap Opportunity Fund Class R6 holds 309K shares representing 0.74% ownership of the company. In it's prior filing, the firm reported owning 241K shares, representing an increase of 22.11%. The firm increased its portfolio allocation in QIPT by 16.85% over the last quarter.
ROFCX - Royce Opportunity Fund Consultant Class holds 298K shares representing 0.71% ownership of the company.
REBYX - U.S. Small Cap Equity Fund Class Y holds 200K shares representing 0.48% ownership of the company. In it's prior filing, the firm reported owning 194K shares, representing an increase of 3.29%. The firm increased its portfolio allocation in QIPT by 58.29% over the last quarter.
PRCGX - Perritt MicroCap Opportunities Fund Investor Class holds 134K shares representing 0.32% ownership of the company. In it's prior filing, the firm reported owning 115K shares, representing an increase of 14.05%. The firm increased its portfolio allocation in QIPT by 48.21% over the last quarter.
IWC - iShares Micro-Cap ETF holds 71K shares representing 0.17% ownership of the company. In it's prior filing, the firm reported owning 68K shares, representing an increase of 3.49%. The firm increased its portfolio allocation in QIPT by 53.49% over the last quarter.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
